Welwyn Garden City, UK, 27th May 2015: CN Bio Innovations, an expert in developing human organ-on-a-chip platforms to test and develop therapeutics for liver diseases and infection, is pleased to announce the commencement of a research study with a fourth pharmaceutical company.

The program will take advantage of CN Bio’s human liver-on-a-chip platform, LiverChip, to study targets implicated in liver disease.

← Back To All News


We like to contact you about: exciting events, campaigns and information about the new products (please note we DO NOT pass on your details to any other organisations), you can opt out of receiving communications at any time.
By submitting your message, you acknowledge that you have read and understood the Privacy Policy

I confirm that I would like CN Bio to stay in touch

We like to contact you about: exciting events, campaigns and information about the new products (please note we DO NOT pass on your details to any other organisations), you can opt out of receiving communications at any time.
By submitting your message, you acknowledge that you have read and understood the Privacy Policy

I confirm that I would like CN Bio to stay in touch

We like to contact you about: exciting events, campaigns and information about the new products (please note we DO NOT pass on your details to any other organisations), you can opt out of receiving communications at any time.
By submitting your message, you acknowledge that you have read and understood the Privacy Policy

I confirm that I would like CN Bio to stay in touch